Earlier, a G/T single nucleotide polymorphism (SNP) in the HMGCR gene was shown to significantly reduce the overall serum lipids response to pravastatin. This study aimed to investigate the relationship of the rs17238540 SNP with coronary heart disease, stroke and cardiovascular disease risk.
Design
Cross-sectional study from the European Prospective Investigation into Cancer and Nutrition-Norfolk cohort.
Methods
Genotype was determined by pyrosequencing 23 011 participants, for whom clinical and biochemical data were available. Baseline risk factors according to genotype were evaluated, and the risk for fatal and nonfatal stroke, ischaemic heart disease and all types of cardiovascular diseases were assessed by logistic regression after approximately 11 years of follow-up.
Results
The G allele carriers presented 1.4 mmHg higher systolic blood pressure and 0.8 mmHg higher diastolic blood pressure than those who were TT carriers. They also presented higher risk of prevalent total (odds ratio: 1.44, 95% confidence interval: 1.05-1.97, P = 0.025) and nonfatal (odds ratio: 1.56, 95% confidence interval: 1.12-2.17, P = 0.009) stroke events compared with the TT individuals in the multivariate models.
Conclusion
An association between the rs17238540 SNP and stroke risk was observed, independent of the effect of the SNP on the blood pressure. The possible mechanisms involved, besides the effect on blood pressure, might be related to pleiotropic functions of the HMGCR, and remain to be explored.
ChasmanDIPosadaDSubrahmanyanLCookNRStantonVPJrRidkerPM.Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA2004; 291:2821–2827.
9.
LeitersdorfELuskeyKL.HgiAI polymorphism near the HMGCR promoter. Nucleic Acids Res1990; 18:5584.
10.
LeitersdorfEHwangMLuskeyKL.ScrFI polymorphism in the 2nd intron of the HMGCR gene. Nucleic Acids Res1990; 18:5584.
11.
ZulianiGHobbsHH.A high frequency of length polymorphism in repeated sequences adjacent to alu sequences. Am J Hum Genet2008; 46:963–969.
12.
HubacekJAPistulkovaHValentaZPoledneR.(TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia. Vasa1999; 28:169–171.
13.
PlatJMensinkRP.Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption. Eur J Clin Invest2002; 32:242–250.
14.
SingerJBHoldaasHJardineAGFellstromBOsIBermannG, et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res2007; 48:2072–2078.
15.
TongYZhangSLiHSuZKongXLiuH, et al. 8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease. Lipids2004; 39:239–241.
16.
HindorffLALemaitreRNSmithNLBisJCMarcianteKDRiceKM, et al. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics2008; 18:677–682.
17.
KhawKTBinghamSWelchALubenRO'BrienEWarehamN, et al. Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). Am J Clin Nutr2004; 80:1397–1403.
18.
WarehamNJJakesRWRennieKLSchuitJMitchellJHenningsS, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr2003; 6:407–413.
19.
DayNOakesSLubenRKhawKTBinghamSWelchA, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer1999; 80:95–103.
20.
WuKBowmanRWelchAALubenRNWarehamNKhawKT, et al. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. Eur Heart J2007; 28:2930–2936.
21.
BinghamSLubenRWelchALowYLKhawKTWarehamN, et al. Associations between dietary methods and biomarkers, and between fruits and vegetables and risk of ischaemic heart disease, in the EPIC Norfolk Cohort Study. Int J Epidemiol2008; 37:978–987.
22.
FreitasRNKhawKTWuKBowmanRJefferyHLubenR, et al. A HMGCR polymorphism is associated with relations between blood pressure and urinary sodium and potassium ratio in the EPIC-Norfolk study. J Am Soc Hypertens2009; 3:238–244.
23.
PoliseckiEMuallemHMaedaNPeterIRobertsonMMcMahonAD, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis2008; 200:109–114.
24.
MarkusHSAlbertsMJ.Update on genetics of stroke and cerebrovascular disease 2005. Stroke2006; 37:288–290.
25.
SchulzUGRFlossmannERothwellPM.Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke2004; 35:819–824.
26.
FlossmannESchulzUGRRothwellPM.Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke2004; 35:212–227.
27.
Jerrard-DunnePCloudGHassanAMarkusHS.Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke2003; 34:1364–1369.
28.
AlbertsMJ.Genetics of cerebrovascular disease. Stroke2004; 35:342–344.
29.
GretarsdottirSThorleifssonGReynisdottirSTManolescuAJonsdottirSJonsdottirT, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet2003; 35:131–138.
30.
EnquobahrieDASmithNLBisJCCartyCLRiceKMLumleyT, et al. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol2008; 101:1683–1688.
31.
MarcianteKDTotahRAHeckbertSRSmithNLLemaitreRNLumleyT, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics2008; 18:535–543.
32.
LemaitreRNHeckbertSRSotoodehniaNBisJCSmithNLMarcianteKD, et al. Beta1-and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens2008; 21:290–296.
33.
EzzatiMLopezADRodgersAVanderHSMurrayCJ.Selected major risk factors and global and regional burden of disease. Lancet2002; 360:1347–1360.
34.
BeckettNS.Prevention of stroke. Eur J Cardiovasc Prev Rehabil2001; 8:257–264.
35.
LewingtonSClarkeRQizilbashNPetoRCollinsR.Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet2002; 360:1903–1913.
36.
BellostaSFerriNBerniniFPaolettiRCorsiniA.Non-lipid-related effects of statins. Ann Med2000; 32:164–176.
37.
SinhaSMyintPKLubenRNKhawKT.Accuracy of death certification and hospital record linkage for identification of incident stroke. BMC Med Res Methodol2008; 8:74.
